GCP
NEOS

GSA Capital Partners’s Neos Therapeutics, Inc NEOS Stock Holding History

GSA Capital Partners’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-39,800
Closed -$66K – 1800
2018
Q4 		$66K Buy
+39,800
New +$112K 0.01% 1247

Other funds holding NEOS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's NEOS Position: Q1 2019 in Review

GSA Capital Partners sold out of Neos Therapeutics, Inc (NEOS) in Q1 2019, closing a stake of 39,800 shares — an estimated $66K sold.

GSA Capital Partners first reported a position in NEOS in Q4 2018 and held it in 1 quarter. The position peaked at $66K in Q4 2018. 63 funds tracked by Wall St. Rank hold NEOS as of Q1 2019.

  • GSA Capital Partners reported no remaining Neos Therapeutics, Inc position as of Q1 2019 after selling out during the quarter.
  • GSA Capital Partners sold 39,800 Neos Therapeutics, Inc shares in Q1 2019, an estimated $66K.
  • GSA Capital Partners first reported a position in Neos Therapeutics, Inc in Q4 2018 and held it in 1 quarter.
  • GSA Capital Partners's Neos Therapeutics, Inc position peaked at $66K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2019.

Based on GSA Capital Partners's 13F filing for Q1 2019, filed 15 May 2019.